Results for tag: "Low Molecular Weight Heparin"

Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases. The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome. Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more